Top

Published in:

01-04-2012 | Basic Neurosciences, Genetics and Immunology - Original Article

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

Authors: Keiko Inaba-Hasegawa, Yukihiro Akao, Wakako Maruyama, Makoto Naoi

Published in: Journal of Neural Transmission | Issue 4/2012

Abstract

Rasagiline and (−)deprenyl (selegiline), irreversible type B monoamine oxidase (MAO-B) inhibitors, protect neuronal cells through gene induction of pro-survival Bcl-2 and neurotrophic factors in the cellular models of neurodegenerative disorders. In this paper, the role of MAO in the up-regulation of neuroprotective Bcl-2 gene by these inhibitors was studied using type A MAO (MAO-A) expressing wild SH-SY5Y cells and the transfection-enforced MAO-B overexpressed cells. Rasagiline and (−)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells. Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (−)deprenyl. MAO-B overexpression inhibited Bcl-2 induction by rasagiline and befloxatone, but did not affect that by (−)deprenyl, suggesting the different mechanisms behind Bcl-2 gene induction by these MAO-B inhibitors. The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.

Abu-Raya S, Tabakman R, Blaugrund E, Trembovier V, Lazaroyici P (2002) Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 434:109–116PubMedCrossRef

Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M (2002) An anti-Parkinson’s disease drug, N-propargyl-1(R)-aminoindan (rasagiline) enhances expression of antiapoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326:105–108PubMedCrossRef

Binda C, Hubalek F, Li M, Herzig Y, Sterling J, Edmondson DE, Mattevi A (2005) Binding of rasagiline-related inhibitors to human monoamine oxidases; a kinetic and crystallographic analysis. J Med Chem 48:8148–8154PubMedCrossRef

Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of l-deprenyl to madopar treatment in Parkinson’s disease: a longterm study. J Neural Transm 64:113–127PubMedCrossRef

Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72:248–254PubMedCrossRef

Chiou SH, Ku HH, Tsai TH, Lin HL, Chen LH, Chien CS, Ho LL-T, Lee CH, Chang YL (2006) Moclobemide upregulated Bcl-2 expression and induce neural stem cell differentiation into serotoninergic neurons via extracellular-regulated kinase pathway. Br J Pharmacol 148:587–598PubMedCrossRef

Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson’s disease: converging insights from neurotoxin and genetic models. Mitochondrion 9:289–298PubMedCrossRef

De Zutter GS, Davis RJ (2001) Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc Natl Acad Sci USA 98:6168–6173PubMedCrossRef

Desagher S, Osen-Sand A, Nichols A, Eskes R, Monteaauit S, Lauper S, Maundrell K, Antonsson B, Martinou J-C (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891–901PubMedCrossRef

Ebadi M, Brown-Borg H, Ren J, Sharma S, Shavali S, ReFacy HE, Carlson EC (2006) Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr Drug Targets 7:1513–1529PubMed

Ekblom J, Oreland L, Chen K, Shih JC (1998) Is there a “non-MAO” macromolecular target for L-deprenyl?: Studies on MAOB mutant mice. Life Sci 63:PL161–PL186CrossRef

Finberg JP, Lamendorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline [N-propargyl-1R-aminoindan]. Adv Neurol 80:495–499PubMed

Fitzgerald JC, Ufer C, Billett EE (2007) A link between monoamine oxidase-A and apoptosis in serum derived human SH-SY5Y cells. J Neural Transm 114:807–810PubMedCrossRef

Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467–469PubMedCrossRef

Hubalek F, Binda C, Ki M, Herzig Y, Sterling J, Youdim MBH, Mattevi A, Edmondson DE (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and its analogues. J Med Chem 47:1760–1768PubMedCrossRef

Hynson RMG, Kelly SM, Price NC, Ramsay RR (2004) Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophy Acta 1472:60–66

Kornhuber J, Konradi C, Mack-Burkhardt F, Riederer P, Heinsen H, Beckmann H (1989) Ontogenesis of monoamine oxidase-A and -B in the human brain frontal cortex. Brain Res 499:81–86PubMedCrossRef

Kraml M (1965) A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14:1684–1686CrossRef

Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MBH, Riederer P, Gerlach M, Oertel WH (2001) Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 108:985–1009PubMedCrossRef

Magyar K, Palfi M, Tabi T, Kalasz H, Szende B, Szöko E (2004) Pharmacological aspects of (−)-deprenyl. Curr Med Chem 11:2017–2031PubMed

Malorni W, Giammarioli P, Pietrangeli E, Agostinelli E, Ciaccio A, Grassili E, Mondove B (1998) Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett 426:155–159PubMedCrossRef

Maragos WF, Tillman PA, Chesnut MD, Jakel RJ (1999) Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. Brain Res 834:168–172PubMedCrossRef

Maruyama W, Takahashi T, Naoi M (1998) (−)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem 70:2510–2515PubMedCrossRef

Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M (2001) Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous neurotoxin, N-methyl(R)salsolinol. J Neurochem 78:727–735PubMedCrossRef

Maruyama W, Takahashi T, Youdim M, Naoi M (2002) The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109:467–481PubMedCrossRef

Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim M, Furukawa S, Nabeshima T, Naoi M (2004) N-Propargyl-1-(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44:393–400PubMedCrossRef

Naoi M, Maruyama W (2009) Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson’s disease. Expert Rev Neurother 9:1233–1250PubMedCrossRef

Naoi M, Maruyama W (2010) Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr Pharmaceu Designs 16:2799–2817

Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y (2006) Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J Neural Transm (71):67–77

Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Eng J Med 361:1268–1278CrossRef

Ou X-M, Chen K, Shih JC (2006) Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc Natl Acad Sci USA 103:10923–10928PubMedCrossRef

Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R, Swedish Parkinson Study Group (2006) Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200–1206PubMedCrossRef

Parkinson Study Group (1993) Effects of tocopherol and deprenyl on progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183CrossRef

Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033–2043PubMed

Shacka JJ, Roth KA (2005) Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:24–39CrossRef

Tatton WG, Ju WYL, Holland D, Tai C, Kwan M (1994) (−)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63:1572–1575PubMedCrossRef

Tazik S, Johnson S, Lu D, Johnson C, Youdim MBH, Stockmeler CA, Ou X-M (2009) Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotoxic Res 15:284–290CrossRef

Yi H, Akao Y, Maruyama W, Chen K, Shih JC, Naoi M (2006a) Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J Neurochem 96:541–549PubMedCrossRef

Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006b) N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21–32PubMedCrossRef

Youdim MBH, Edmondson D, Tipton KF (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci 7:295–309PubMedCrossRef

Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MBH, Le W (2008) Comparison of neuroprotective and neurorestorative capacities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopamine degeneration. J Neurochem 105:1970–1978PubMedCrossRef

Title: Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase
Authors: Keiko Inaba-Hasegawa
Yukihiro Akao
Wakako Maruyama
Makoto Naoi
Publication date: 01-04-2012
Publisher: Springer Vienna
Published in: Journal of Neural Transmission / Issue 4/2012
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-011-0730-6

ACC 2024 Congress

Springer Medicine

Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Instability of syllable repetition in progressive supranuclear palsy

Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in Parkinsonian brains

Pilot study on HTR2A promoter polymorphism, −1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive–compulsive disorder

The default mode network integrity in patients with Parkinson’s disease is levodopa equivalent dose-dependent

Synaptic protein expression is regulated by a pro-oxidant diet in APPxPS1 mice

Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT2A/2C receptors